Friday, Sep 22, 2023
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Education Today
    • Reviews
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | India | Booster Dose Neutralizes Covid 19 Omicron Variant Study

Booster dose neutralizes COVID-19 Omicron variant: Study

Washington: An international team of researchers recently studied the sensitivity of Omicron to antibodies compared with the currently dominant Delta variant. The study about this variant has been published in the ‘Nature Journal’. The new COVID-19 Omicron variant is more transmissible than the Delta variant. However, its biological characteristics are still relatively unknown. In South […]

By Telangana Today
Published Date - 03:33 PM, Sun - 16 January 22
Booster dose neutralizes COVID-19 Omicron variant: Study
whatsapp facebook twitter telegram

Washington: An international team of researchers recently studied the sensitivity of Omicron to antibodies compared with the currently dominant Delta variant.

The study about this variant has been published in the ‘Nature Journal’.

The new COVID-19 Omicron variant is more transmissible than the Delta variant. However, its biological characteristics are still relatively unknown.

In South Africa, the Omicron variant replaced the other viruses within a few weeks and led to a sharp increase in the number of cases diagnosed. Analyses in various countries indicate that the doubling time for cases is approximately 2 to 4 days. Omicron has been detected in dozens of countries, including France, and became dominant by the end of 2021.

In a new study supported by the European Union’s Health Emergency Preparedness and Response Authority (HERA), scientists from the Institut Pasteur and the Vaccine Research Institute, in collaboration with KU Leuven (Leuven, Belgium), Orleans Regional Hospital, Hospital Europeen Georges Pompidou (AP-HP) and Inserm, studied the sensitivity of Omicron to antibodies compared with the currently dominant Delta variant.

The aim of the study was to characterize the efficacy of therapeutic antibodies, as well as antibodies developed by individuals previously infected with SARS-CoV-2 or vaccinated, in neutralizing this new variant.

The scientists from KU Leuven isolated the Omicron variant of SARS-CoV-2 from a nasal sample of a 32-year-old woman who developed moderate COVID-19 a few days after returning from Egypt. The isolated virus was immediately sent to scientists at the Institut Pasteur, where therapeutic monoclonal antibodies and serum samples from people who had been vaccinated or previously exposed to SARS-CoV-2 were used to study the sensitivity of the Omicron variant.

The scientists used rapid neutralization assays, developed by the Institut Pasteur’s Virus and Immunity Unit, on the isolated sample of the Omicron virus. This collaborative multidisciplinary effort also involved the Institut Pasteur’s virologists and specialists in the analysis of viral evolution and protein structure, together with teams from Orleans Regional Hospital and Hospital Europeen Georges Pompidou in Paris.

The scientists began by testing nine monoclonal antibodies used in clinical practice or currently in preclinical development. Six antibodies lost all antiviral activity, and the other three were 3 to 80 times less effective against Omicron than against Delta.

The antibodies Bamlanivimab/Etesevimab (a combination developed by Lilly), Casirivimab/Imdevimab (a combination developed by Roche and known as Ronapreve), and Regdanvimab (developed by Celtrion) no longer had any antiviral effect against Omicron. The Tixagevimab/Cilgavimab combination (developed by AstraZeneca under the name Evusheld) was 80 times less effective against Omicron than against Delta. “We demonstrated that this highly transmissible variant has acquired significant resistance to antibodies. Most of the therapeutic monoclonal antibodies currently available against SARS-CoV-2 are inactive,” commented Olivier Schwartz, co-last author of the study and Head of the Virus and Immunity Unit at the Institut Pasteur.

The scientists observed that the blood of patients previously infected with COVID-19, collected up to 12 months after symptoms, and that of individuals who had received two doses of the vaccine, taken five months after vaccination, barely neutralized the Omicron variant. But the sera of individuals who had received a booster dose of Pfizer, analyzed one month after vaccination, remained effective against Omicron.

Five to 31 times more antibodies were nevertheless required to neutralize Omicron, compared with Delta, in cell culture assays. These results help shed light on the continued efficacy of vaccines in protecting against severe forms of the disease. “We now need to study the length of protection of the booster dose. The vaccines probably become less effective in offering protection against contracting the virus, but they should continue to protect against severe forms,” explained Olivier Schwartz. “This study shows that the Omicron variant hampers the effectiveness of vaccines and monoclonal antibodies, but it also demonstrates the ability of European scientists to work together to identify challenges and potential solutions. While KU Leuven was able to describe the first case of Omicron infection in Europe using the Belgian genome surveillance system, our collaboration with the Institut Pasteur in Paris enabled us to carry out this study in record time,” commented Emmanuel Andre, co-last author of the study, a Professor of Medicine at KU Leuven (Katholieke Universiteit Leuven) and Head of the National Reference Laboratory and the genome surveillance network for COVID-19 in Belgium. “There is still a great deal of work to do, but thanks to the support of the European Union’s Health Emergency Preparedness and Response Authority (HERA), we have clearly now reached a point where scientists from the best centres can work in synergy and move towards a better understanding and more effective management of the pandemic,” added Emmanuel.

The scientists concluded that the many mutations in the spike protein of the Omicron variant enabled it to largely evade the immune response. Ongoing research is being conducted to determine why this variant is more transmissible from one individual to the next and to analyze the long-term effectiveness of a booster dose.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


Telangana Today Whatsapp
  • Follow Us :
  • Tags
  • Covid-19
  • COVID-19 Omicron
  • Delta variant
  • HERA

Related News

  • COVID-19: India reports 55 fresh cases on Friday

    COVID-19: India reports 55 fresh cases on Friday

  • Unlocking the Covid code: Cough sounds hold vital clues to severity, reveals study

    Unlocking the Covid code: Cough sounds hold vital clues to severity, reveals study

  • Israel to start vaccinations against new Omicron substrains

    Israel to start vaccinations against new Omicron substrains

  • Utilizing cough sound analysis for assessing severity in COVID-19 patients

    Utilizing cough sound analysis for assessing severity in COVID-19 patients

  • TV host Jimmy Kimmel contracts COVID-19

    TV host Jimmy Kimmel contracts COVID-19

  • Calcutta HC orders investigation into school student’s suicide, overseeing by police commissioner

    Calcutta HC orders investigation into school student’s suicide, overseeing by police commissioner

Latest News

  • Kamal Nath: State polls critical for Madhya Pradesh’s future

    3 mins ago
  • BJP preparing strategies to target BRS, Cong welfare programs

    10 mins ago
  • Dr Nawab Mir Nasir Ali Khan receives ‘AsiaOne Diplomatic Excellence Award 2023′

    10 mins ago
  • Sonnalli Seygall signs a 3-film deal with Jio Studios

    10 mins ago
  • Sai Pallavi squashes ‘baseless’ marriage rumours

    11 mins ago
  • 9,824 candidates secure seats in TS EAMCET 2023 BiPC final phase allotment

    13 mins ago
  • Sebi empanels 34 entities for conducting forensic investigation of mutual funds, AMCs, trustees

    19 mins ago
  • Chennur, Sirpur (T) become launching pads for politicians

    21 mins ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam